PCH
XFOR icon

Polar Capital Holdings’s X4 Pharmaceuticals XFOR Stock Holding History

Polar Capital Holdings’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-166,667
Closed -$9.7M – 302
2023
Q2 		$9.7M Buy
+166,667
New +$8.56M 0.05% 198

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Polar Capital Holdings's XFOR Position: Q4 2023 in Review

Polar Capital Holdings sold out of X4 Pharmaceuticals (XFOR) in Q4 2023, closing a stake of 250,000 shares — an estimated $8.18M sold.

Polar Capital Holdings first reported a position in XFOR in Q3 2023 and held it in 1 quarter. The position peaked at $8.18M in Q3 2023. 93 funds tracked by Wall St. Rank hold XFOR as of Q4 2023.

  • Polar Capital Holdings reported no remaining X4 Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Polar Capital Holdings sold 250,000 X4 Pharmaceuticals shares in Q4 2023, an estimated $8.18M.
  • Polar Capital Holdings first reported a position in X4 Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Polar Capital Holdings's X4 Pharmaceuticals position peaked at $8.18M in Q3 2023.
  • 93 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2023.

Based on Polar Capital Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.